THERAPY DOSSIER · th-467267e84f23

Human bone marrow mesenchymal stromal cells (hMSC), with or without cyclosporin A immunosuppression

Biologic · Cyclophilin A modulator

Evidence & regulatory context

Mechanism: Cyclophilin A modulator
Target: CHEMBL1949 (Cyclophilin A)
Injury models: TBI
Reported indication: Not recorded
First approval: 1983
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Ciclosporin; Ciclosporin A; Cyclosporin A; Sandimmune; Neoral; Gengraf; Restasis; Ikervis
Note: Not recorded

Clinical trials 4

4 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01446640 ↗Injury indicationPHASE1/PHASE2unknown

Phase I/II autologous bone marrow derived mesenchymal stem cells in spinal cord injury

Spinal Cord Injury

Enrolment: 20 · Results not recorded

NCT01909154 ↗Injury indicationPHASE1completed

Phase I pilot: local administration of autologous bone marrow stromal stem cells in traumatic spinal cord injury

Spinal Cord Injury

Enrolment: 12 · Results not recorded

NCT04288934 ↗Injury indicationPHASE1completed

Safety and effectiveness of mesenchymal stem cells in spinal cord injury patients (BM-MSC)

Spinal Cord Injuries

Enrolment: 20 · Results not recorded

NCT02165904 ↗Injury indicationPHASE1completed

Subarachnoid administration of adult autologous mesenchymal stromal cells in incomplete SCI

Spinal Cord Injury

Enrolment: 10 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24246661 ↗2013Reported benefit

Immunosuppression does not affect human bone marrow mesenchymal stromal cell efficacy after transplantation in traumatized mice brain.

MouseTBIUnspecifiedC57Bl/6MaleIntracerebroventricular infusion150,000 cells in 5 microlitres24 h after injury

Model: Traumatic brain injury (controlled experimental TBI with sham surgery controls)

hMSC produced comparable functional recovery (sensorimotor and cognitive) and structural protection (reduced contusion volume, vessel rescue, reduced gliotic scar, increased neurogenesis) in both immunocompetent and immunosuppressed mice, indicating long-term efficacy is not dependent on immunosupp…

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…